The Breakthrough Prize Foundation awarded researchers involved in developing gene therapies for blindness and sickle cell ...

Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency   AskBio Inc. (AskBio), a ...

Three scientists have won the 2026 Breakthrough Prize for developing Luxturna — the world's first FDA-approved gene therapy ...

Three Philadelphia scientists won a $3 million Breakthrough Prize for developing the first FDA-approved gene therapy for a genetic disease, prize sponsors announced Saturday. Their work created a ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...

To Ocugen CEO Shankar Musunuri, Ph.D., most gene therapy biotechs today lack vision. | Many gene therapy outfits focus on ...

Neurogene is looking to make the leap from a clinical biotech to a commercial biopharma with its lead gene therapy and has ...

Key takeawaysResults from a UCLA-led clinical trial for sickle cell disease reveal the unique challenges of treating blood disorders with gene therapy ...

Three life-science prizes were awarded for advances in gene therapies. Opthalmologists Jean Bennett and Albert Maguire, and ...

For example, the Genome Foundry at Concordia University's Centre for Applied Synthetic Biology (CASB) in Montréal, Quebec, ...

Married couple Jean Bennett and Albert Maguire developed Luxturna, which helped a patient see their child’s face for the first time ...

Precedence Research introduces its Advanced Cell and Gene Therapy Intelligence Platform, turning complex data into actionable ...